Masitinib in Patients With Symptomatic Mild to Moderate COVID-19

NCT05047783 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

78

Enrollment

INDUSTRY

Sponsor class

Conditions

Covid19
SARS-CoV2 Infection
Coronavirus Disease 2019

Interventions

DRUG: Masitinib Mesylate
DRUG: Placebo

Sponsor

AB Science